Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s found a contender with preclinical data indicating it can lead to ...

Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...

Designing effective lexicons is a critical component of any communications surveillance program, yet even mature teams encounter avoidable pitfalls that diminish accuracy, create operational strain, ...

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential ...